BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.94 CNY | +0.87% |
|
+1.22% | -6.46% |
| Sales 2024 * | 6.12B 844M | Sales 2025 * | 7.3B 1.01B | Capitalization | 47.69B 6.58B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.35B 186M | Net income 2025 * | 1.63B 226M | EV / Sales 2024 * | 7.8 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 6.53 x |
| P/E ratio 2024 * |
35.1
x | P/E ratio 2025 * |
28.9
x | Employees | 4,858 |
| Yield 2024 * |
0.52% | Yield 2025 * |
0.78% | Free-Float | 45.51% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.87% | ||
| 1 week | +1.22% | ||
| Current month | +7.07% | ||
| 1 month | +10.54% | ||
| 3 months | +8.47% | ||
| 6 months | +7.19% | ||
| Current year | -6.46% |
1 week
27.76
29.28
1 month
25.3229.28
Current year
24.2031.35
1 year
23.0032.73
3 years
14.9338.58
5 years
13.4344.58
10 years
5.6844.58
| Managers | Title | Age | Since |
|---|---|---|---|
Dao Xing Fu
CEO | Chief Executive Officer | 60 | 17-04-24 |
Hui Chuan Yang
CHM | Chairman | 57 | 11-05-31 |
Bo Tian
IRC | Investor Relations Contact | - | 06-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yan Fang
BRD | Director/Board Member | 56 | 20-06-22 |
Hui Chuan Yang
CHM | Chairman | 57 | 11-05-31 |
Fen Ling Gu
BRD | Director/Board Member | 61 | 20-06-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.66% | 2 M€ | -20.02% | - | |
| 0.61% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 28.94 | +0.87% | 10,764,570 |
| 24-04-19 | 28.69 | +1.88% | 9,945,064 |
| 24-04-18 | 28.16 | -1.02% | 9,767,785 |
| 24-04-17 | 28.45 | +1.83% | 11,748,100 |
| 24-04-16 | 27.94 | -2.27% | 13,289,540 |
End-of-day quote Shanghai S.E., April 21, 2024
More quotes
BEIJING TIANTAN BIOLOGICAL PRODUCTS CORPORATION LIMITED is a China-based company principally engaged in the biopharmaceutical businesses. The Companyâs primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines, influenza vaccinations, bacterial vaccines, human serum albumin (HSA) and intravenous immunoglobulin (IVIG), among others. The Company mainly distributes its products within domestic markets and to Hong Kong markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
28.94
CNY
Average target price
31.86
CNY
Spread / Average Target
+10.07%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -6.46% | 6.58B | |
| -2.79% | 85.68B | |
| +5.53% | 41.4B | |
| -24.99% | 28.22B | |
| +54.63% | 24.64B | |
| -7.19% | 16.98B | |
| -34.20% | 13.29B | |
| -17.31% | 11.66B | |
| -11.43% | 11.65B | |
| -1.57% | 8.18B |
- Stock Market
- Equities
- 600161 Stock
